Company profile: GSK
1.1 - Company Overview
Company description
- Provider of pharmaceutical medicines, vaccines, and consumer healthcare products.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GSK
Propagenix
HQ: United States
Website
- Description: Provider of healthcare technology platforms for translational biomedical research, including EpiX technology to expand primary epithelial cells without genetic modification, CR feeder-cell culture to replicate epithelial cells, engineered bi-layered skin constructs, airway epithelium models and theranostic assays, and collaborative and sponsored research for drug discovery and toxicology screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Propagenix company profile →
Sunovion
HQ: United States
Website
- Description: Provider of therapeutic products discovered, developed and commercialized for central nervous system and respiratory disorders and other illnesses. Portfolio includes Latuda for schizophrenia and bipolar depression; Aptiom for partial-onset seizures; Gemtesa/vibegron for overactive bladder; Myfembree for heavy menstrual bleeding due to uterine fibroids; Orgovyx for advanced prostate cancer; LUNESTA; and XOPENEX.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sunovion company profile →
Sirona Biochem
HQ: Canada
Website
- Description: Provider of biotechnology solutions including diabetes therapeutics, cosmetic skin depigmenting and anti-aging agents, biological ingredients and cancer vaccine antigens. Offers compounds such as TFC-1067, LIP-01 and SGLT2 inhibitors, enabled by GlycoMim technology and fluorination chemistry to stabilize carbohydrate-based molecules and enhance pharmaceutical and cosmetic properties.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirona Biochem company profile →
Altor BioScience
HQ: United States
Website
- Description: Provider of immunotherapeutic agents for cancer, viral infections, and autoimmune diseases, including ANKTIVA (N‑803), an IL‑15 receptor agonist for non‑muscle invasive bladder cancer; investigational cancer and viral therapies and vaccines (personalized neoepitope-based, HIV, HPV); Tri‑Ad5 vaccine for Lynch syndrome; STAR Fusion reagents for diagnosis/targeting, STAR Multimer reagents for research; and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altor BioScience company profile →
Vertex Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule drugs for serious diseases, including cystic fibrosis medicines, and research and development of therapies for sickle cell disease, type 1 diabetes, APOL1-mediated kidney disease, pain management, and beta thalassemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vertex Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GSK
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GSK
2.2 - Growth funds investing in similar companies to GSK
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GSK
4.2 - Public trading comparable groups for GSK
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →